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Many genetic neurological disorders exhibit variable expression within affected families, often exempliﬁed by variations in disease
age at onset. Epistatic effects (i.e. effects of modiﬁer genes on the disease gene) may underlie this variation, but the mechanistic
basis for such epistatic interactions is rarely understood. Here we report a novel epistatic interaction between SPAST and the
contiguous gene DPY30, which modiﬁes age at onset in hereditary spastic paraplegia, a genetic axonopathy. We found that
patients with hereditary spastic paraplegia caused by genomic deletions of SPAST that extended into DPY30 had a signiﬁcantly
younger age at onset. We show that, like spastin, the protein encoded by SPAST, the DPY30 protein controls endosomal tubule
ﬁssion, trafﬁc of mannose 6-phosphate receptors from endosomes to the Golgi, and lysosomal ultrastructural morphology. We
propose that additive effects on this pathway explain the reduced age at onset of hereditary spastic paraplegia in patients who are
haploinsufﬁcient for both genes.
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Introduction
A hallmark of many genetic neurodegenerative disorders is
variable expression within affected families, often exempli-
ﬁed by variations in disease age at onset. In some diseases,
typically those caused by triplet repeat expansions, this
variability is explained by the dynamic nature of the mu-
tation (Orr and Zoghbi, 2007). However, in conditions
where the pathogenic mutation is static, epistatic effects,
where alleles at other genes modify the disease phenotype,
are often suggested as an explanation. The underlying bio-
logical basis for such epistatic effects may involve additive
deleterious effects on cellular pathways in which the pro-
teins encoded by the disease and modiﬁer gene both par-
ticipate. However, in human single gene disease in general,
and in neurodegenerative disease in particular, there are
few examples where the underlying functional basis for
such an epistatic effect has been explained.
The hereditary spastic paraplegias (HSPs) are a group
of single gene disorders in which the main pathological
feature is a dying-back axonopathy involving the longest
corticospinal tract axons (Harding, 1993; Reid, 1999;
Fink, 2006). Although HSP is caused by mutations in
many genes (Hensiek et al., 2015), mutations in SPAST
(also known as SPG4) are by far the most frequent, affect-
ing up to 60% of families with autosomal dominant HSP,
and around 10–20% of cases unselected by family history
(Hazan et al., 1999; Fonknechten et al., 2000; Sauter et al.,
2002; Schule et al., 2016).
SPAST encodes the microtubule severing ATPase enzyme
spastin, which uses the energy of ATP hydrolysis to create
internal breaks within microtubules (Errico et al., 2002;
Evans et al., 2005; Roll-Mecak and Vale, 2008; Lumb
et al., 2012). Spastin localizes to sites of contact between
the endoplasmic reticulum and endosomes, and we re-
ported recently that it is required for efﬁcient ﬁssion of
endosomal tubules from the endosome, which occurs spe-
ciﬁcally at these contact sites (Allison et al., 2013, 2017).
Defective tubule ﬁssion in cells lacking spastin manifests as
an increase in the number and length of tubules attached to
the endosomal body. This is accompanied by defective sort-
ing of receptors that trafﬁc away from endosomes via this
tubular compartment, including of mannose 6-phosphate
receptors (M6PRs) (Allison et al., 2013, 2017). M6PRs
normally cycle between endosomes and the trans Golgi net-
work; at the trans Golgi network they capture M6P-tagged
lysosomal enzymes for delivery back to the endolysosomal
degradative compartment. Inhibition of M6PR trafﬁc away
from the endosome in cells lacking spastin causes accumu-
lation of M6PRs in the endolysosomal compartment and
reduced availability at the trans Golgi network, resulting in
diminished capture of lysosomal enzymes. This causes mis-
trafﬁcking of lysosomal enzymes and a failure of enzyme
delivery to endolysosomes, which in turn causes the devel-
opment of abnormally enlarged lysosomes with character-
istic ultrastructural morphology in spastin-HSP cellular
models. Importantly, this includes primary neurons from
a spastin knock-in mouse expressing a disease-associated
spastin ATPase domain mutation, and induced pluripotent
stem cell (iPSC)-derived spastin-HSP patient neurons
(Connell et al., 2016; Allison et al., 2017). As a similar
lysosomal abnormality has been observed in several other
subtypes of HSP, we have proposed that it represents a
common pathological mechanism for the disease
(Khundadze et al., 2013; Renvoise et al., 2014; Hirst
et al., 2015; Varga et al., 2015; Allison et al., 2017).
Spastin-HSP shows considerable variation in age at onset,
both within and between families. This can range from
early childhood to late adult life (Fonknechten et al.,
2000; Lindsey et al., 2000). The SPAST mutational spec-
trum is broad, incorporating nonsense, frameshift, splice
site and missense mutations, strongly suggesting that the
disease mechanism is haploinsufﬁciency in most, if not
all, cases (Fonknechten et al., 2000). With regard to these
small genetic alterations, to date there is no unambiguous
genotype–phenotype correlation related to age at onset of
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disease, although the presence of a hypomorphic variant
(S44L) in combination with a disease causing mutation re-
duces age at onset (Yip et al., 2003; Svenson et al., 2004;
Shoukier et al., 2009).
The contribution of large genomic rearrangements to the
SPAST mutational spectrum was recognized by studies that
used cDNA analysis and Southern blotting to identify single
or multi-exon deletions (Sauter et al., 2002; Iwanaga et al.,
2005). Subsequent development of a SPAST-targeted multi-
plex ligation-dependent probe ampliﬁcation (MLPA) assay
revealed in two studies that large genomic abnormalities
account for up to 20% of disease-associated SPAST muta-
tions (Beetz et al., 2006; Depienne et al., 2007). These ini-
tial MLPA studies compared clinical characteristics of
deletion carriers versus carriers of conventional ‘small’ mu-
tations and in one an earlier age at onset in SPAST dele-
tion-positive patients was found (Depienne et al., 2007).
Numerous reports on SPAST rearrangements have been
published since (see Human Gene Mutation Database web-
site: http://www.hgmd.cf.ac.uk/ac/index.php), and the asso-
ciation of large deletions with reduced age at onset was
again observed (Chelban et al., 2017). The question of
how different mutational classes, which all likely act via
a haploinsufﬁciency mechanism, could have differing clin-
ical outcomes has not been resolved.
In this study we conﬁrm that exonic deletion of SPAST is
associated with a signiﬁcant reduction in age at onset of
HSP, but show that this reduction is accounted for by a
subset of patients in whom the deletion extends into the
contiguous gene DPY30. The protein encoded by DPY30
has been implicated in endosome-to-Golgi trafﬁc (Xu et al.,
2009). We therefore investigated whether the DPY30 pro-
tein regulates similar endosomal trafﬁcking steps to spastin.
We found that cultured cells lacking DPY30 had increased
endosomal tubulation, defective trafﬁc of M6PR from
endosomes to the Golgi apparatus, and abnormal lyso-
somal ultrastructural appearances that were highly similar
to those seen in spastin-HSP models. Thus we propose that
haploinsufﬁciency of spastin and DPY30 causes reduced
age at onset in HSP via additive deleterious effects on endo-
somal membrane trafﬁc and consequent lysosomal func-
tion. This study provides support for the general
hypothesis that epistasis can be caused by additive effects
on cellular pathways in which the genes involved
participate.
Materials and methods
Patients and ethical approval
Subjects who donated fibroblast lines
The patients included were of western European ethnic origin
with typical characteristics of pure HSP and mutations in
SPAST, as summarized below. The control was an unrelated
healthy subject from the same ethnic background, with no
history of movement disorder or neurological disease.
Human ﬁbroblasts were obtained from dermal punch biopsies
from the upper arm, following Institutional Review Board ap-
proval (Nr. 4120: Generierung von humanen neuronalen
Modellen bei neurodegenerativen Erkrankungen) and written
informed consent at the movement disorder clinic at the
Department of Molecular Neurology, Universita¨tsklinikum
Erlangen (Erlangen, Germany). Further details of the patients
and cell lines derived from them are as follows:
Patient 1 was a 51-year-old male with SPAST deletion invol-
ving exons 2–9, with age at onset 39 years. Patient 2 was a 50-
year-old female with mutation involving deletion of exons 1–7
of SPAST and exons 1–5 of DPY30, who had an age at onset
below 20 years of age.
The control was a healthy 41-year-old male subject.
Fibroblast were designated UKERf1JF-X-001 from the control
subject, UKERf29U-X-001 from Patient 1 and UKERfVRV-X-
001 from Patient 2.
Patients who participated in genetic studies
Samples were obtained from peripheral blood samples from
patients with clinically pure HSP, obtained after informed writ-
ten consent. Age at onset information was available for all
included patients. Where required, the research was performed
according to protocols reviewed and approved by local insti-
tutional review boards (IRBs); Cambridge Local Research
Ethics Committee, Cambridge, UK (LREC 96/268); Paris-
Necker ethics committee (approval RBM 01-29 and RBM
03-48 to A.D.; patients gave informed consent and blood sam-
ples were collected in accordance with local French regula-
tions); the ethics committee of the Medical Faculty of
Tu¨bingen University (GeNeMove study; approval 277/2004).
Antibodies
Rabbit polyclonal DPY30, RBBP5, ASH2L and BIG1 antibo-
dies were from Bethyl Laboratories. Rabbit polyclonal anti-
GFP (6556) and mouse monoclonal anti-M6PR (ab2733)
were from Abcam. Mouse monoclonal anti-Snx1 was obtained
from BD Transduction Laboratories. Mouse monoclonal anti-
LC3 was obtained from MBL (clone 4E12, catalogue number
M152-3). Rabbit polyclonal anti-spastin 86-340 and CD8
antibodies were produced as previously described (Seaman,
2004; Connell et al., 2009). Mouse monoclonal anti-LAMP1
(H4A3) was obtained from Santa Cruz Biotechnology. Rabbit
polyclonal anti-GAPDH (2118) was from Cell Signalling
Technology. Alexa Fluor 488 and 568 labelled secondary
antibodies for immunoﬂuorescence were obtained from
Molecular Probes. Peroxidase conjugated secondary antibodies
for western blotting were obtained from Sigma.
Stable cell lines
A HeLa cell line stably expressing GFP-GOLPH3 and CD8-
CIMPR was a gift from Matthew Seaman (Seaman, 2004).
Cell culture
HeLaM cells were maintained as previously described (Connell
et al., 2009). HeLaM cells stably expressing GFP-GOLPH3
and CD8-CIMPR were cultured in the presence of both
500 mg/ml Geneticin (Invitrogen) and 1 mg/ml Puromycin
(Sigma-Aldrich). Human ﬁbroblasts were cultured in Iscove’s
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modiﬁed Dulbecco’s medium containing 15% foetal bovine
serum (FBS, Invitrogen) and 1 penicillin/streptomycin and
passaged using TrypLETM (all Invitrogen).
MLPA assays
For MLPA we used probe mixes P165 and P211 (MRC-
Holland, The Netherlands) according to the manufacturer’s
recommendations. Analysis of raw MLPA data, and calcula-
tion of zygosity were performed as described previously (Beetz
et al., 2006).
Reverse transcriptase-PCR
Fibroblasts were grown to 50% conﬂuence, trypsinized, har-
vested, and homogenized in a glass-glass potter in order to
isolate total RNA with the RNeasy kit (Qiagen) following
the manufacturer’s instructions. Quantitative real-time PCR
was performed in a 20 ml ampliﬁcation mixture consisting of
Brilliant II SYBR Green QPCR Master Mix (Stratagene),
cDNA (equivalent to 25 ng reverse-transcribed RNA) and
primers (250 nM ﬁnal concentration each; sequences avail-
able upon request). Transcripts were ampliﬁed with
Rotor Gene 6000 (Corbett Life Science, now Qiagen).
Expression levels were calculated using the Pfafﬂ equation
(Pfafﬂ, 2001) and normalized against GAPDH and HMBS.
To derive values for Patients 1 and 2, geometrical means
from three runs were expressed as fractions of the control
sample.
Short interfering RNA transfection
Cells were transfected with the relevant siRNAs, using
OligofectamineTM transfection reagent (Invitrogen), according
to a protocol modiﬁed from Connell et al. (2009). Brieﬂy, cells
were plated into a well of a 6-well plate and transfected after
24 h. Cells were harvested 48–96 h later. The efﬁciency of
siRNA knock-down was veriﬁed by immunoblotting cell lys-
ates and/or by immunoﬂourescence microscopy of ﬁxed cells,
with an antibody against the relevant protein. siRNA was used
at a ﬁnal concentration of 10 nM for each gene targeted.
Target sequences and manufacturers for siRNA were as
follows:
SPAST: SPAST 1: 50-GAACUUCAACCUUCUAUAA (Dharmacon
D-014070-01); SPAST 3: 50-UAUAAGUGCUGCAAGUUUA
(Dharmacon D-014070-03).
DPY30 10: 50-CAGACAACGUUGAGAGAAU (Dharmacon J-
014923-10); DPY30 11: 50-CCACCAAAUCCCAUUGAAU
(Dharmacon J-014923-11); DPY30 12: 50-UUUACAUGAUUAAG
AGGCA (Dharmacon J-014923-12).
ASH2L: ASH2L 5: 50-AAAGAUGGCUAUCGGUAUA (Dharmacon
J-019831-05); ASH2L 6: 50-GGACCAUGCUUCAAGUAUC (Dhar
macon J-019831-06); ASH2L 8: 50- GAGACAGAAUCAUCUAAUG
(Dharmacon J-019831-08).
RBBP5: RBBP5 5: 50-UAACACGGCAGAUCGAAUA (Dharmacon
J-012008-05); RBBP5 6: 50-UAUAGAACUUCAAGGAGUA
(Dharmacon J-012008-06); RBBP5 8: 50-GAUGGAACUUUGGAU
UGUA (Dharmacon J-012008-08).
BIG1 (now known as ARFGEF1): BIG1 5: GUCCAAAUGUC
CUCGCAUA (Dharmacon J-012207-05); BIG1 6: GAACAG
GUCUCCAACAAUU (Dharmacon J-012207-05); BIG1 7:
GAUCACAAAUGGAUGGUUA (Dharmacon J-012207-05); BIG1
8: GAUGAUAGAUUGUCAGUCU (Dharmacon J-012207-05).
Immunofluorescence microscopy
Cells were ﬁxed at room temperature in 3.8% (v/v) formalde-
hyde in phosphate-buffered saline (PBS) and permeabilized in
PBS containing 0.1% (v/v) saponin (Sigma) or 0.1% (v/v)
TritonTM X-100 (Sigma). Coverslips were labelled with pri-
mary and secondary antibodies as previously described
(Connell et al., 2009). Slides were analysed with a Zeiss
LSM880 confocal microscope (100 NA 1.40 oil immersion
objective, 37C), or Zeiss AxioImager Z2 Motorized Upright
Microscope (63 NA 1.40 oil immersion objective, room tem-
perature, Zeiss Axiocam 506). Co-localization of immuno-
ﬂuorescence signals was quantiﬁed using Volocity Image
Analysis Software. Images were subsequently processed using
Adobe Photoshop and Illustrator and ZEN analysis software.
Endosomal tubulation counts on
fixed cells
Cells were processed for immunoﬂuorescence microscopy and
imaged with a Zeiss AxioImager Motorized Upright
Microscope under a 63 /1.4NA oil immersion objective as
described above. Tubulation was quantiﬁed using one of two
methods: (i) as described previously (Allison et al., 2017),
images of 100 cells per condition were randomized and the
percentage of cells with at least one tubule longer than 2 mm
was counted blind; or (ii) images were analysed computation-
ally using a system described previously, which determined the
number of tubules per cell, the mean length of the longest
tubule in each cell and the percentage of cells containing a
tubule (Newton and Reid, 2016).
Cation independent M6PR trafficking
assay
Following a 48-h siRNA knock-down of the relevant protein,
HeLa cells stably expressing GFP-GOLPH3 and CD8-ciM6PR
tail were subject to ciM6PR trafﬁcking assays as described in
Seaman (2007). Brieﬂy, following incubation in medium con-
taining anti-CD8 at 4C, cells were incubated for 30min at
37C before ﬁxation and processing for immunoﬂuorescence
microscopy with a Zeiss LSM880 confocal microscope as
described above. Co-localization of appropriate proteins was
quantiﬁed using Volocity Image Analysis Software.
Magic Red cathepsin B assays
Cells were subject to siRNA knock-down with the relevant
siRNAs and incubated with transfection reagents for 96 h.
Cells were harvested with trypsin, pelleted at 900 rpm for
3min, and then resuspended in 250ml Dulbecco’s modiﬁed
Eagle medium (DMEM) supplemented with 10 ml of a 26
stock solution (in DMSO) of Magic RedTM cathepsin B (Bio-
Rad) and incubated for 1 h at 37C. Following the incubation
cells were washed in PBS, resuspended in 500ml DMEM and
ﬂuorescence at 561 nm analysed by ﬂuorescence activated cell
sorting (FACS) on a BD Fortessa analyser.
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Lysosome quantification
To determine the percentage of cells with large lysosomes, ﬁxed
cells labelled with LAMP1 were processed for immunoﬂuores-
cence microscopy as described above, and imaged with a Zeiss
AxioImager Motorized Upright Microscope as described above.
One hundred cells were recorded per experimental condition.
Images were randomized and the largest lysosome per cell mea-
sured using ZEN analysis software. Lysosomes were classiﬁed as
‘large’ if they exceeded 1.8mm in diameter.
Lysosome pH measurement
Lysosomal pH measurement was performed as described pre-
viously (Allison et al., 2017). Brieﬂy, HeLa cells were incuba-
tion for 4 h at 37C in medium containing 1mg/ml dextran
conjugated to Oregon Green (pH sensitive) or tetramethyl-
rhodamine (pH insensitive). This was followed by a 20-h un-
labelled chase before imaging with live cell microscopy at 37C
using a Zeiss LSM780 microscope (63 NA 1.40 oil object-
ive). Individual puncta were identiﬁed with ImageJ and the
ratio of Oregon Green to tetramethylrhodamine signal was
quantiﬁed for each punctum. The pH of each punctum was
determined against a standard curve of ﬂuorescence ratio, gen-
erated using cells incubated with 10 mm nigericin and 5mm
monensin in buffers ranging from pH 4.5 to 6.5.
Electron microscopy
HeLa cells were grown on Thermanox (Nunc) plastic
coverslips and ﬁxed with 2% paraformaldehyde, 2.5% glutaral-
dehyde, 0.1M cacodylate buffer (pH 7.2). Samples were post-
ﬁxed with 1% osmium tetroxide: 1.5% potassium ferricyanide
before being incubated with 1% tannic acid to enhance contrast.
Cells were dehydrated using increasing percentages of ethanol
before being embedded onto EPON stubs. Resin was cured over-
night at 65C and coverslips were removed using a heat block.
Ultrathin (50–70nm) conventional sections were cut using a dia-
mond knife mounted to a Reichert Ultracut S ultramicrotome.
Sections were collected onto copper grids. Grids were stained
using lead citrate. Sections were viewed on a FEI Tecnai trans-
mission electron microscope at a working voltage of 80kV.
Statistical analysis
Statistical analyses were done with paired two-tailed (or in the
case of the M6PR trafﬁcking assay one-tailed) t-tests, using
GraphPad Prism 5.01 for Windows (GraphPad Software, San
Diego). Histograms show mean  standard error of the mean
(SEM).
Results
Decreased age at onset in carriers of
SPAST deletions correlates with
involvement of exon 1
We ﬁrst set out to understand the discrepancy between the
two initial reports that characterized the effect of SPAST
exonic deletions on age at onset (Beetz et al., 2006;
Depienne et al., 2007). We noticed an increased proportion
of families with deletions involving exon 1 in the study that
reported a younger age at onset [8 of 24 families (33%)
in Depienne et al. (2007) versus 3 of 13 families (23%)
in Beetz et al. (2006)]. This disproportion was even
greater when numbers of patients with age at onset data
(rather than numbers of families) were compared [16/44 or
36% with an exon 1 deletion in Depienne et al. (2007)
versus 4/31 or 13% in Beetz et al. (2006)]. We reanalysed
these data to test whether earlier age at onset was signiﬁ-
cantly related to involvement of SPAST exon 1. Indeed,
mean age at onset for the 20 exon 1 deletion patients in
both studies was 23.0 (16.3) years, whereas it was 31.8
(16.7) years for the 55 patients with deletions that did
not involve exon 1 (Fig. 1A, B and Supplementary Table 1).
Unfortunately any potential impact on severity or progres-
sion could not be analysed because of insufﬁcient patient
data. We concluded that SPAST exon 1 deletion is asso-
ciated with a younger age at onset of HSP.
Contiguous deletion of DPY30 is
associated with decreased age at
onset in patients with SPAST exon 1
deletions
Considering that all SPAST exonic deletions (and indeed
most, if not all, spastin mutations) almost certainly act
via haploinsufﬁciency, the ﬁnding of clinical differences be-
tween families with the same mutational mechanism was
puzzling and so we explored it further (Burger et al., 2000;
Fonknechten et al., 2000; Beetz et al., 2006). Of note, in a
Japanese family a genomic deletion involving SPAST exons
1–4 extended into the adjacent gene DPY30, which is ubi-
quitously expressed, lies 24 kb upstream and is ‘head-to-
head’ with SPAST, an arrangement that has been present in
evolution since at least cartilaginous ﬁsh (Supplementary
Fig. 1). This family had a young mean age at onset of
10.4 (18.8) years (Miura et al., 2011). We therefore
hypothesized that reduced age at onset in patients with
exon 1 SPAST deletions is explained by the involvement
of DPY30 in some families. To test this, we developed a
novel MLPA assay in which several probes target the 50 end
of the SPAST gene, the DPY30 gene, and the intergenic
region (Fig. 1C). Moreover, we analysed additional families
with deletions involving exon 1. Together with the families
reported in the previous studies (Beetz et al., 2006;
Depienne et al., 2007; Miura et al., 2011), our cohort
now included 21 families (53 patients) with SPAST exon
1 deletions, and 55 patients with SPAST deletions not
involving exon 1 (Supplementary Table 2). In 10 of the
families with SPAST exon 1 deletions (31 patients), the
deleted region included at least the 50UTR and exons 1
and 2 of DPY30, while for the remaining 11 families (22
patients), DPY30 involvement was inconclusive (Fig. 1C).
These genotypes were correlated with age at onset. Mean
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age at onset for carriers of deletions affecting both genes
was signiﬁcantly lower (at 20.2  18.1 years) than in pa-
tients with SPAST deletions that spared DPY30
(31.8  16.7 years). Cases with inconclusive DPY30 in-
volvement, which likely represent a mixture of the former
two classes, had an intermediate age at onset (28.5  17.8
years) (Fig. 1D and Supplementary Table 2). The mean age
at onset in the SPAST-only deletion patients is similar to
that reported with conventional ‘small’ SPAST mutations
(Chelban et al., 2017). We concluded that the earlier age at
onset observed in patients with SPAST exon deletions is
accounted for by families where the deletion also involves
DPY30.
Reduced expression of DPY30 does
not affect SPAST transcription
We sought a mechanistic explanation for the apparent epi-
static effect between SPAST and DPY30. The best charac-
terized role of DPY30 is in transcriptional regulation via
histone methylation as part of a multiprotein complex
termed WRAD (WDR5, RBBP5, ASH2L and DPY30),
which binds to SET1 family methytransferases and stimu-
lates methylation of histone H3 at lysine 4 (Ernst and
Vakoc, 2012). However, several non-canonical roles have
also been described, including a role in the cytoplasm
where it has been suggested to promote endosome-to-
Golgi trafﬁc, although this has not been directly tested
(Xu et al., 2009; Ali and Tyagi, 2017).
In view of the transcriptional role of DPY30, we exam-
ined whether haploinsufﬁciency of DPY30 affects SPAST
transcription. We performed quantitative RT-PCR experi-
ments on RNA extracted from ﬁbroblasts from (i) a control
subject; (ii) an HSP patient with a deletion involving spastin
only (exons 2–9; Patient 1); and (iii) a patient with a
deletion involving SPAST and DPY30 (SPAST exons
1–17 + DPY30 exons 1–5; Patient 2), using primers amp-
lifying two independent fragments of the DPY30 or SPAST
transcripts. The patients with the SPAST-only deletion and
the SPAST+DPY30 deletion had similar levels of SPAST
transcript (40% of the transcript levels of the control)
Figure 1 Age at onset of symptoms is reduced in HSP patients with SPAST deletions that involve DPY30. (A) MLPA probes in the
standard commercially available assay (P165) target each SPASTexon with one or more probes (arrows), but do not analyse neighbouring regions/
genes. Deletions that involve SPASTexon 1 (black box in the lower part of the figure) can be distinguished from deletions that spare SPASTexon 1
(white boxes as examples). (B) Age at onset in patients where SPAST exon 1 is part of the deletion is significantly younger than age at onset in
patients with other SPAST deletions. (C) In a modified MLPA assay (P211), most probes against internal SPASTexons were removed (stippled grey
arrows), and replaced by probes that target the adjacent gene DPY30 or the intergenic region (bold arrows). This enabled classification of SPAST
exon 1 deletion carriers into those in which DPY30 was also at least partially deleted (examples shown by black boxes in the lower part of the
panel), and those in which DPY30 deletion status was inconclusive, as the deletion involved intergenic probes but no probes targeting the DPY30
coding region (e.g. grey box). (D) Age at onset in patients with SPAST deletions, stratified on the status of whether the deletion also involved
DPY30. Age at onset was significantly younger in patients where the SPAST deletion extended into DPY30 coding exons, when compared to
carriers of SPAST deletions that do not involve SPAST exon 1 (and, therefore, definitely spare DPY30). Histograms show mean  SEM, P-values
generated by two-tailed Student’s t-test.
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(Fig. 2A and B). We concluded that DPY30 does not
signiﬁcantly inﬂuence SPAST transcription.
DPY30 regulates endosomal tubula-
tion and endosome-to-Golgi traffic of
M6PR
As spastin regulates endosomal tubule ﬁssion and endo-
some-to-Golgi trafﬁc, we next asked whether DPY30 inﬂu-
ences these phenotypes. In cells lacking spastin, defective
endosomal tubule ﬁssion causes an increase in the
number of long tubules labelled by sorting nexin 1
(SNX1), a marker of tubules that are involved in endo-
some-to-Golgi trafﬁc of M6PRs (Allison et al., 2013,
2017). Interestingly, an increased proportion of cells lack-
ing DPY30 developed long endosomal tubules compared to
control cells (Fig. 3A–C). This effect was seen with three
separate siRNA oligonucleotides, conﬁrming that it was not
due to an off-target effect of siRNA transfection. The size
of the effect was not as large as observed in cells lacking
spastin, but importantly we saw an additive effect of com-
bined spastin and DPY30 depletion (Fig. 3A and B). We
examined whether other members of the WRAD complex
also regulate endosomal tubulation. While we found no
signiﬁcant effects with depletion of any individual complex
member, in each case there was a non-signiﬁcant trend
towards increased endosomal tubulation (Supplementary
Fig. 2). We therefore cannot exclude the idea that
DPY30’s role in regulation of endosomal tubulation is as
part of this complex.
We next examined whether DPY30 affects endosome-to-
Golgi trafﬁc. A previous report described an abnormal dis-
tribution of M6PR in cells lacking DPY30, but did not
directly examine endosome-to-Golgi trafﬁc (Xu et al.,
2009). To test this, we employed an assay using a HeLa
cell line stably expressing CD8-epitope tagged M6PR tail
(Seaman, 2007). Some tagged protein is present at the
plasma membrane and subject to endocytosis and subse-
quent trafﬁcking to the trans Golgi network, so anti-CD8
antibody feeding experiments can be used to report on
endosome-to-Golgi trafﬁc of M6PR. In wild-type cells, we
found strong co-localization between CD8-M6PR and the
Golgi apparatus 30min after antibody internalization.
However, in cells lacking either spastin, DPY30 or both
proteins, we saw a reduction in the amount of co-localiza-
tion between CD8-M6PR and the Golgi 30min after
internalization, consistent with inhibition of endosome-to-
Golgi trafﬁc of the receptor (Fig. 4A and B). M6PR
distribution in these cells tended to be more peripheral,
consistent with the previous report (Xu et al., 2009).
There was a non-signiﬁcant trend towards an additive
effect on M6PR endosome-to-Golgi trafﬁc in cells lacking
both DPY30 and spastin. Similarly, using a probe (Magic
Red-cathepsin B) that ﬂuoresces on cleavage by the M6P-
tagged lysosomal enzyme cathepsin B, we saw slight reduc-
tions in enzyme activity with depletion of DPY30 or spastin
alone, with signiﬁcant additive effects of combined deple-
tion (Supplementary Fig. 3).
Figure 2 DPY30 does not affect SPAST transcription. (A) Fibroblast mRNA samples from a patient with a SPAST-only deletion (Patient 1,
white box), from a patient with a SPAST+DPY30 deletion (Patient 2, black box), and from a healthy control were analysed by exon-spanning
qPCRs as indicated above the schematics of the genes. The expression levels (normalized to two housekeeping genes) in the patient samples
relative to the control sample are shown in B. Values plotted are means  SEM, P-values generated with paired two-tailed t-tests.
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As cells lacking DPY30 have increased SNX1 endosomal
tubulation accompanied by reduced endosome-to-Golgi
trafﬁc of cargo that normally trafﬁcs via SNX1 tubules,
we concluded that, like spastin, DPY30 promotes ﬁssion
of SNX1-labelled endosomal tubules. Thus DPY30 is a
novel component of the machinery that drives endosomal
tubule ﬁssion.
Cells lacking DPY30 have abnormal
lysosomal morphology
Cellular models of spastin-HSP, including primary neurons
from a spastin-HSP mouse model and patient iPSC-derived
neurons, develop enlarged lysosomes and a characteristic
ultrastructural appearance. This abnormal ultrastructure af-
fects lysosomes of all sizes and comprises accumulation of
abnormal membrane material within the lysosome (Connell
et al., 2016; Allison et al., 2017).
Against this background, we examined whether DPY30
inﬂuences lysosomal size or ultrastructural morphology.
HeLa cells depleted of DPY30 showed no increase in the
mean size of the largest lysosome per cell or in the percentage
of cells with lysosomes 41.8mm diameter (Fig. 5A and B).
However, by electron microscopy we observed the presence
of highly abnormal lysosomes. These lysosomes contained
accumulations of membrane material that could be arranged
in loose tangles or in dense honeycomb networks, and which
was strikingly similar to structures seen in cells lacking spas-
tin (Fig. 5C) (Allison et al., 2017). Lysosomes in cells lacking
DPY30 or spastin showed minimal co-localization with the
autophagic marker LC3, indicating that they are predomin-
antly not autolysosomes (Supplementary Fig. 4).
We then examined whether DPY30 inﬂuences lysosomal
phenotypes in cells lacking spastin. We examined lysosomal
size, postulating that DPY30 and spastin depletion would
have additive effects. Surprisingly we found that depletion
Figure 3 DPY30 regulates endosomal tubulation and endosome-to-Golgi traffic. (A) HeLa cells were transfected with the siRNA
oligonucleotides indicated, then fixed and labelled for endogenous SNX1. In each experimental condition 100 cells were analysed and the
percentage of cells with at least one SNX1 tubule42 mm in length was reported. The mean percentage of cells with endosomal tubules in n = 4
biological repeats is shown in B. Corresponding immunoblots to verify protein depletion are shown in C. P-values were generated by paired two-
tailed t-test, error bars show mean  SEM. Scale bar = 10mm in light micrographs.
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of DPY30 in cells lacking spastin rescued the increase in the
proportion of cells with enlarged lysosomes observed in cells
lacking only spastin (Fig. 5A and B). We found a similar
rescue effect following depletion of two other members of
the WRAD complex, RBBP5 and Ash2L (Supplementary
Fig. 5). However, the abnormal ultrastructural morphology
seen in cells lacking spastin was not rescued by additional
DPY30 depletion, as highly abnormal lysosomes were pre-
sent in cells depleted of both proteins (Fig. 5C).
Lysosomes in cells lacking spastin become more acidic
(Allison et al., 2017). We examined lysosomal pH in cells
lacking DPY30, and found them to be signiﬁcantly more
alkaline than in wild-type cells. Depletion of both DPY30
and spastin resulted in a mean lysosomal pH that was sig-
niﬁcantly lower than in wild-type cells, but higher than in
spastin-only depleted cells (Supplementary Fig. 6). As it is
not known whether the increased acidity in cells lacking
spastin is a direct pathological mechanism or a homeostatic
response in an attempt to clear the substrate accumulation
within the lysosome, the functional consequences of this
raised pH are unclear.
We concluded from these experiments that DPY30 acts in
the same way as spastin to prevent accumulation of abnor-
mal material in lysosomes, but has differing effects on the
regulation of lysosomal size and pH.
Depletion of the DPY30 binding
partner BIG1 phenocopies DPY30
depletion
As haploinsufﬁciency of DPY30 increases severity of the
spastin-HSP phenotype by reducing age at onset, the
Figure 4 DPY30 regulates endosome-to-Golgi traffic. (A) Anti-CD8 antibody uptake experiments in HeLa cells stably expressing CD8-
ciM6PR and GFP-GOLPH3 (a Golgi marker), and subjected to DPY30, spastin alone or spastin plus DPY30 depletion by siRNA knock-down (KD),
using a pool of siRNAs to the proteins indicated. Cells were fixed 30min after antibody uptake and CD8 and GFP signal visualized by im-
munofluorescence microscopy. Mean  SEM co-localization between the markers (Pearson’s correlation) at 30min is shown in the histogram
B (n = 6). Scale bar = 10mm. P-values calculated using paired one-tailed t-tests.
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Figure 5 DPY30 influences lysosomal morphology. (A) HeLa cells were transfected with a pool of siRNAs targeting the proteins
indicated, then fixed and imaged for endogenous LAMP1. The percentage of cells with lysosomes 41.8 mm (n = 100 cells per condition) was
counted and the mean of six biological repeats is plotted in B. (C) HeLa cells were transfected with a pool of siRNAs targeting the proteins
indicated, fixed and processed for electron microscopy. Lysosomes containing abnormal intralumenal content are indicated by arrows. (D) HeLa
cells were transfected with a pool of siRNAs targeting the proteins indicated, then fixed and imaged for endogenous LAMP1. The percentage of
cells with lysosomes 41.8 mm (n = 100 cells per condition) was counted and the mean of four biological repeats is plotted in E. P-values were
generated by paired two-tailed t-test, error bars show mean  SEM. Scale bar = 10mm in light micrographs; 500 nm in electron micrographs.
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rescue of spastin-depletion-induced lysosomal enlargement
(although not lysosomal ultrastructural abnormalities) by
depletion of DPY30 is at ﬁrst sight counter-intuitive. We
therefore explored a potential mechanism of this in more
detail. DPY30 interacts with two guanine nucleotide ex-
change factor (GEF) proteins, ARFGEF1 and ARFGEF2
[also known as Brefeldin-inhibited GEFS 1 and 2 (BIG1
and BIG2)]. The simplest model for the functional relation-
ship between these proteins is that DPY30 promotes the
action of BIG1/2, as like DPY30, inhibition of BIG1/2
causes increased endosomal tubulation and blocks in endo-
some to Golgi trafﬁc, suggestive of defective endosomal
tubule ﬁssion. However, BIG1/2 also promote vesicular
transport from the trans Golgi network to the endosomal
pathway. (Ishizaki et al., 2008; Manolea et al., 2008; Xu
et al., 2009; Xia et al., 2010; D’Souza et al., 2014). Indeed,
at steady state both cytoplasmic DPY30 and BIG1/2 pre-
dominantly localize to the trans Golgi network, and so in-
hibition of BIG1/2 caused by loss of DPY30 would be
expected to reduce membrane trafﬁc from the trans Golgi
network to the endosomal pathway, as well as affecting
endosomal tubule ﬁssion. We therefore predicted that de-
pletion of a BIG protein would phenocopy the effects of
DPY30 depletion on lysosomal size. We focused on BIG1,
as DPY30 recruitment to the trans Golgi network requires
this protein, and found that the increased lysosomal size
phenotype found in cells lacking spastin was indeed rescued
by depletion of BIG1 (Fig. 5D and E) (Xu et al., 2009).
Discussion
In this study we identify an epistatic interaction between
SPAST and DPY30 that inﬂuences age at onset in spastin-
HSP. Mutations in SPAST account for up to 60% of fa-
milial HSP cases in northern Europe and North America,
and of these spastin-HSP cases 10–20% may be caused by
large rearrangements, predominantly deletions (Beetz et al.,
2006; Depienne et al., 2007; Sulek et al., 2013; Schule
et al., 2016; Chelban et al., 2017). We now show that
when these deletions also involve the adjacent gene
DPY30 [as happened in at least 20% of SPAST deletion
cases reported in Beetz et al. (2006) and Depienne et al.
(2007)], mean age at onset of HSP is signiﬁcantly reduced.
This provides an explanation for the previously perplexing
observation that patients with SPAST whole exon deletions
have a younger mean age at onset than patients with other
mutational classes that are also expected to cause
haploinsufﬁciency.
The DPY30 gene deletions identiﬁed were contiguous
with SPAST deletions, and almost certainly arose as part
of the same mutational event in each family; 70% of
SPAST copy number variants are caused by an Alu-repeat
based mechanism, with the Alu-rich genomic architecture
of SPAST (40% of the gene’s sequence are Alu elements)
making it prone to these events (Boone et al., 2014). Of
note, DPY30 has an even higher fraction of Alu-derived
sequence (51%). However, in the general population copy
number variants involving DPY30 appear to be rare, with
deletions having a frequency of 1 and duplications a fre-
quency of 5 in 32 850 in non-Finnish European alleles
(ExAC database) (Lek et al., 2016). In addition, missense
variants and variants predicted to result in possible loss of
function via splicing effects are also individually and col-
lectively rare in DPY30; the most common putative splice
site mutation listed in ExAC has an allele frequency of
50.0003 (ExAC database) (Lek et al., 2016). For this
reason, we consider it unlikely that polymorphisms in
DPY30 will make a substantial contribution to inﬂuencing
age at onset in patients with spastin-HSP not caused by
exon deletions. In addition, in view of the relatively small
effect of DPY30 depletion (which is almost complete by
immunoblotting) versus spastin depletion on endosomal
tubulation and M6PR trafﬁc, we consider it unlikely that
haploinsufﬁciency of DPY30 could itself cause HSP.
Knockout of Dpy30 in mice causes embryonic lethality,
and so it is again unlikely that recessive DPY30 mutations
cause HSP (Bertero et al., 2015).
Variability in age at onset of neurogenetic diseases is
often ascribed to effects of genetic background, i.e. the ef-
fects a gene or genes that modify the function of the disease
gene. Such modiﬁer genes are being systematically sought,
through candidate gene or genome-wide efforts in disease
populations (Mehta et al., 2007; Gan-Or et al., 2015; Pla-
Martin et al., 2015; Jiang et al., 2016; Velez et al., 2016).
The mechanism of such effects could include participation
of the encoded proteins in the same cell biological pathway
or protein complex, or the existence of a regulatory rela-
tionship between the encoded proteins. However, there are
very few examples where modiﬁer genes have been identi-
ﬁed in genetic neurodegenerative disease and where the
underlying cell biological mechanism of the epistatic effect
has also been characterized. Thus, by showing that DPY30,
like spastin, regulates endosomal sorting of M6PR and con-
sequently lysosomal morphology, we provide both a mech-
anistic explanation for an epistatic effect in a genetic
neurodegenerative disease, and proof of the principle that
this may be due to functional effects on the same pathway.
We found a consistent trend towards increased endoso-
mal tubulation when we depleted WRAD complex mem-
bers other than DPY30, and we saw a similar rescue of the
lysosomal size phenotype associated with lack of spastin
when we depleted other WRAD components. These results
are consistent with the ﬁndings that other WRAD complex
members regulate M6PR localization, and suggest that the
effect of DPY30 on membrane trafﬁc pathways is as part of
the WRAD complex, and presumably involves protein
methylation (Xu et al., 2009). The cytoplasmic targets of
the WRAD complex, and the functional consequences of
WRAD-mediated methylation of cytoplasmic proteins, are
obscure. However, in general, methylation has been shown
to inﬂuence several cytoplasmic biochemical pathways, for
example, by altering binding afﬁnities between pathway
components, or regulating phosphorylation status (Biggar
Epistatic interaction in HSP BRAIN 2018: Page 11 of 14 | 11
Downloaded from https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awy034/4902997
by University of Cambridge user
on 27 February 2018
and Li, 2015). In view of their interaction with DPY30 and
their known role in regulating endosomal tubulation and
trans Golgi network to endosome vesicular trafﬁc, we
speculate that DPY30 and the WRAD complex may methy-
late BIG1/2, which could promote interaction and activa-
tion of their downstream targets such as the GTPase ARF1,
to drive these processes (Gillingham and Munro, 2007;
Ishizaki et al., 2008; Manolea et al., 2008; Xu et al.,
2009; Xia et al., 2010; D’Souza et al., 2014). Such a mech-
anism would be consistent with our ﬁnding that loss of
BIG1 phenocopies the effect of loss of DPY30 in rescuing
the increased lysosomal size in cells lacking spastin. Final
lysosomal size in cells lacking spastin and DPY30 is likely
to be governed by the balance of effects of loss of DPY30
in inhibiting endosomal tubule ﬁssion (which will tend to
increase lysosomal size) or trans Golgi network to endo-
some trafﬁc (which will tend to reduce lysosomal size)
(Fig. 6). Importantly, although the size of the lysosomes
is normalized in cells lacking both DPY30 and spastin,
their ultrastructure was still highly abnormal. Indeed, we
would expect that lack of DPY30 and spastin would have
an additive effect on lysosomal functional abnormalities, as
it would reduce trafﬁc of enzymes to lysosomes by two
mechanisms: (i) reduced capture of lysosomal enzymes be-
cause of reduced availability of M6PR at the trans Golgi
network, due to defective SNX1 endosomal tubule ﬁssion;
and (ii) defective BIG1-mediated vesicular transport from
the trans Golgi network to the endolysosomal system,
caused by lack of DPY30.
In summary, we have identiﬁed and delineated a cell bio-
logical mechanistic basis for an epistatic effect between
DPY30 and spastin that inﬂuences age at onset in a signiﬁ-
cant subgroup of spastin-HSP patients. Our study supports
the principle that alterations in genes that encode proteins
functioning in the same cell biological pathway can explain
epistatic effects in human disease in general, and neurode-
generative disease in particular. Furthermore, it also sug-
gests a potential therapeutic strategy, as we predict that
manipulations that increase DPY30 function could increase
age at onset in spastin-HSP.
Figure 6 Model of role of spastin and DPY30 in membrane
traffic pathways, and how these might influence lysosomes
when disrupted. (A) In the normal situation, M6PR cycles between
endosomes and the Golgi, capturing lysosomal enzymes at the Golgi
for delivery back to the endolysosomal system. The sorting endo-
some matures into the multivesicular body and the accompanying
acidification promotes dissociation of lysosomal enzymes from
M6PR. During the maturation process, empty M6PR is sorted back
to the Golgi in endosomal tubules that require spastin, DPY30 and
likely BIG1/2 to break efficiently from the parent endosome. (B) In
cells lacking spastin endosomal tubule fission is deficient (1), so
M6PR traffic from the endosome-to-Golgi is inhibited and M6PR
accumulates in the endolysosomal pathway. Lack of M6PR at the
Golgi means that lysosomal enzymes are not captured, and instead
are secreted (2) rather than delivered efficiently to the endolyso-
somal system (3). These effects result in the development of
enlarged (through failure of membrane sorting away from the lyso-
somal pathway and substrate accumulation), morphologically abnor-
mal (through substrate accumulation) lysosomes (4). (C) In cells
lacking spastin and DPY30, traffic of M6PR from the endosomes to
the Golgi is inhibited by inefficient endosomal tubule fission (1), but
in addition DPY30 promotes BIG1/2-mediated traffic out of the
Golgi, so lack of DPY30 inhibits Golgi to endosome traffic (2). Both
effects reduce enzyme delivery to the lysosome, but will tend to have
opposing impacts on lysosomal size. Thus in cells lacking both spastin
and DPY30, lysosomal size depends on the balance between these
two effects, but effects on enzyme delivery could be additive (3),
especially in the case of haploinsufficiency of both.
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